PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change From Baseline to Week 52 in the PSPRS Outcome
Timeframe: Baseline to Week 52
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Timeframe: Baseline to Week 52
Number of Participants Experiencing Serious Adverse Events (SAEs)
Timeframe: Baseline to Week 52